Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic controlEl-ghoroury, Eman Aa; Raslan, Hala Mb; Badawy, Ehsan Ac; El-Saaid, Gamila Sc; Agybi, Mervat Hc; Siam, Ibrahemb; Salem, Sohair IcBlood Coagulation & Fibrinolysis: June 2009 - Volume 20 - Issue 4 - p 248–251 doi: 10.1097/MBC.0b013e3283254549 Original Articles Abstract Author Information This study investigated the level of platelet malondialdehyde (MDA) as a marker of oxidative stress and coenzyme Q10 (CoQ10) as an index of antioxidant capacity in patients with type 2 diabetes mellitus and their relation to glycemic control. The study group consisted of 28 patients with type 2 diabetes mellitus (10 men and 18 women) with mean age of 48 ± 2 years. Ten healthy individuals, age and sex matched with the patients, were used as a control group. Laboratory investigations in the form of lipid profile, glycosylated hemoglobin, plasma MDA, platelet MDA and plasma CoQ10 were assessed for all patients and controls. The study revealed that plasma and platelet MDA, as a marker of oxidative stress, were significantly higher in diabetic patients than in controls. The level of CoQ10, as antioxidant capacity, was significantly lower in diabetic patients than in controls. There was a negative correlation between plasma CoQ10 concentrations and glycosylated hemoglobin. Type 2 diabetic patients are at increased risk of oxidative stress manifested by increased plasma MDA as well as platelet MDA and decreased CoQ10, and this oxidative stress increases with poor glycemic control. aClinical and Chemical Pathology Department, Egypt bInternal Medicine Department, Egypt cMedical Biochemistry Department, National Research Center, Cairo, Egypt Received 12 May, 2008 Revised 13 October, 2008 Accepted 13 October, 2008 Correspondence to Dr Eman A. El-ghoroury, MD, Clinical and Chemical Pathology Department, National Research Center, Cairo, Egypt Tel: +20 222665493; e-mail: firstname.lastname@example.org © 2009 Lippincott Williams & Wilkins, Inc.